ALHC · NASDAQ · STOCK
Alignment Healthcare (ALHC) Stock Analysis
$13.53
52W $12.70 – $25.12
56/100
$2.81B
67.9
1.11
Is ALHC Bullish or Bearish?
Mixed.
Innellis AI committee rates Alignment Healthcare, Inc. (ALHC) Watch with a composite score of 56/100
, based on 6 analysts with 33% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.82 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.18 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 37.2% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.80) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 20.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 37.2% YoY -- genuine top-line momentum — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 69.0 is expensive by classic value standards — Value
- Price-to-book of 22.0x prices in significant intangible value — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value
- Price structure making lower highs and lower lows — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
- High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
56/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 80%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · High confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ ROE of 20.0% shows genuine earnings power backing the valuation
− P/E of 69.0 is expensive by classic value standards
Growth Analyst
bullish
83
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 37.2% YoY -- genuine top-line momentum
Technical Analyst
neutral
46
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 56.2 to 56.2.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
44.4
Neutral
MACD Histogram
0.266
Bullish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Mixed
Support
$13.05
Resistance
$21.05
Bollinger %B
0.56
Inside Bands
Price vs Moving Averages
EMA 9
$13.55
Below
EMA 21
$14.08
Below
EMA 50
$15.83
Below
EMA 200
$17.75
Below
Fundamental Analysis
Valuation
33
Growth
94
Profitability
1
Financial Health
69
Cash Flow
70
Valuation
P/E Ratio
67.9×
P/B Ratio
10.59×
PEG Ratio
0.00
Dividend Yield
0.00%
52W High
$25.12
52W Low
$12.70
Quality & Growth
ROE
-40.4%
ROA
-6.8%
Gross Margin
1254.9%
Operating Margin
120.2%
Revenue Growth YoY
—
Debt / Equity
1.25
AI Fundamental Assessment
P/E ratio of 67.9 (rich relative to a 15-40x range); Price-to-book of 10.6x; PEG ratio of 0.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -0.4%; Return on assets of -0.1%; Net margin of 0.9%; Gross margin of 12.5%; Current ratio of 1.70 (healthy short-term liquidity); Debt-to-equity of 1.25; Free cash flow per share is positive (0.99); Most recent quarter beat estimates by 28.8%; 4 consecutive earnings beats; EPS growth accelerating (+200.0% -> +240.0% QoQ); Analyst estimates rising over recent quarters
Get the Full ALHC Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →